Linden, IgE, Serum
Use
The test is used to establish a diagnosis of an allergy to linden and to define the allergen responsible for eliciting signs and symptoms. It identifies allergens responsible for allergic response or anaphylactic episodes, confirms sensitization prior to immunotherapy, and investigates the specificity of allergic reactions to insect venom allergens, drugs, or chemical allergens. Testing for IgE antibodies in individuals previously treated with immunotherapy is not useful in determining residual clinical sensitivity, and it's also not useful when medical management doesn't depend on identifying allergen specificity.
Special Instructions
Not provided.
Limitations
Some individuals with clinically insignificant sensitivity to allergens may have measurable levels of IgE antibodies in serum, and test results must be interpreted in the clinical context. False-positive results for IgE antibodies may occur in patients with markedly elevated serum IgE (>2500 kU/L) due to nonspecific binding to allergen solid phases. Testing for IgE antibodies is not useful in patients previously treated with immunotherapy when residual sensitivity needs to be determined.
New York Approved
Methodology
Immunoassay (FEIA)
Biomarkers
IgE
Protein
LOINC Codes
- 11179-9 - Linden IgE Qn
- 11179-9 - Linden IgE Qn
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL for every 5 allergens requested
Minimum Volume
0.3 mL for 1 allergen
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial
Causes for Rejection
None specified
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 90 days |